Skip to main content Accessibility help
×
Home

Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013

  • Lauren Epstein (a1) (a2), Isaac See (a1), Jonathan R. Edwards (a1), Shelley S. Magill (a1) and Nicola D. Thompson (a1)...

Abstract

OBJECTIVES

To determine the impact of mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBIs) on central-line–associated bloodstream infection (CLABSI) rates during the first year of MBI-LCBI reporting to the National Healthcare Safety Network (NHSN)

DESIGN

Descriptive analysis of 2013 NHSN data

SETTING

Selected inpatient locations in acute care hospitals

METHODS

A descriptive analysis of MBI-LCBI cases was performed. CLABSI rates per 1,000 central-line days were calculated with and without the inclusion of MBI-LCBIs in the subset of locations reporting ≥1 MBI-LCBI, and in all locations (regardless of MBI-LCBI reporting) to determine rate differences overall and by location type.

RESULTS

From 418 locations in 252 acute care hospitals reporting ≥1 MBI-LCBIs, 3,162 CLABSIs were reported; 1,415 (44.7%) met the MBI-LCBI definition. Among these locations, removing MBI-LCBI from the CLABSI rate determination produced the greatest CLABSI rate decreases in oncology (49%) and ward locations (45%). Among all locations reporting CLABSI data, including those reporting no MBI-LCBIs, removing MBI-LCBI reduced rates by 8%. Here, the greatest decrease was in oncology locations (38% decrease); decreases in other locations ranged from 1.2% to 4.2%.

CONCLUSIONS

An understanding of the potential impact of removing MBI-LCBIs from CLABSI data is needed to accurately interpret CLABSI trends over time and to inform changes to state and federal reporting programs. Whereas the MBI-LCBI definition may have a large impact on CLABSI rates in locations where patients with certain clinical conditions are cared for, the impact of MBI-LCBIs on overall CLABSI rates across inpatient locations appears to be more modest.

Infect. Control Hosp. Epidemiol. 2015;37(1):2–7

Copyright

Corresponding author

Address correspondence to Lauren Epstein, MD, MSc, Epidemic Intelligence Service, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-16, Atlanta, Georgia 30329-4027 (Xdd0@cdc.gov).

Footnotes

Hide All

PREVIOUS PRESENTATION: The results of this analysis were presented in part at ID Week 2014 Philadelphia, Pennsylvania, October 9, 2014. Abstract #1284.

Footnotes

References

Hide All
1. KM., P. Public Reporting of Infections and the CLABSI Mandate. Infection Control Today Web site. http://www.infectioncontroltoday.com/articles/2011/01/public-reporting-of-infections-and-the-clabsi-mandate.aspx. Published January 17, 2011. Accessed February 2, 2015.
2. Pehar, M, Ristaino, P, Budd, A, et al. Application of the National Healthcare Safety Network (NHSN) Central Line Associated Bloodstream Infection (CLA-BSI) Definition to Oncology Patients: Impact in the Trenches, 2010. Presented at the International Conference on Healthcare-Associated Infections, March 18–22, 2010. Abstract #660.
3. Fraser, TG, Gordon, SM. CLABSI rates in immunocompromised patients: a valuable patient centered outcome? Clin Infect Dis 2011;52:14461450.
4. Steinberg, JP, Robichaux, C, Tejedor, SC, Reyes, MD, Jacob, JT. Distribution of pathogens in central line-associated bloodstream infections among patients with and without neutropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition. Infect Control Hosp Epidemiol 2013;34:171175.
5. Sexton, DJ, Chen, LF, Anderson, DJ. Current definitions of central line-associated bloodstream infection: is the emperor wearing clothes? Infect Control Hosp Epidemiol 2010;31:12861289.
6. Rettig, SL, Gross, KA, Ditaranto, S, et al. Central line-associated bloodstream infections (CLABSI) in oncology patients: the impact of mucositis on CLABSI rates, 2011. Presented at the SHEA Annual Scientific Meeting, April 1–4, 2011, Dallas, Texas. Abstract #232.
7. Digiorgio, MJ, Fatica, C, Oden, M, et al. Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies. Infect Control Hosp Epidemiol 2012;33:865868.
8. Worth, LJ, Slavin, MA, Brown, GV, Black, J. Catheter-related bloodstream infections in hematology: time for standardized surveillance? Cancer 2007;109:12151226.
9. Tancrede, CH, Andremont, AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 1985;152:99103.
10. Blijlevens, NM, Donnelly, JP, De Pauw, BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000;25:12691278.
11. NHSN v7.1 Release Notes. The Centers for Disease Control and Prevention Web site. http://www.cdc.gov/nhsn/pdfs/commup/Release-Notes-v7-1.pdf. Published February 2013. Accessed February 2, 2015.
12. See, I, Iwamoto, M, Allen-Bridson, K, Horan, T, Magill, SS, Thompson, ND. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition. Infect Control Hosp Epidemiol 2013;34:769776.
13. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection). The Centers for Disease Control and Prevention Web site. http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Published January 2015. Accessed February 3, 2015.
14. National Action Plan to Prevent Health Care-Assocation Infections: Road Map to Elimination. Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services Web site. http://www.health.gov/hai/prevent_hai.asp. Accessed March 23, 2015.
15. Gaur, AH, Bundy, DG, Gao, C, et al. Surveillance of hospital-acquired central line-associated bloodstream infections in pediatric hematology-oncology patients: lessons learned, challenges ahead. Infect Control Hosp Epidemiol 2013;34:316320.
16. Freeman, JT, Elinder-Camburn, A, McClymont, C, et al. Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivity. Infect Control Hosp Epidemiol 2013;34:8992.
17. Metzger, KE, Rucker, Y, Callaghan, M, et al. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology and stem cell transplant patients. Infect Control Hosp Epidemiol 2015;36:119124.
18. Dudeck, MA, Edwards, JR, Allen-Bridson, K, et al. National Healthcare Safety Network report, data summary for 2013, device-associated module. Am J Infect Control 2015;43:206221.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed